Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Accured Expenses (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Change in Accured Expenses data on record, last reported at -$58348.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 116.23% year-over-year to -$58348.0; the TTM value through Dec 2025 reached -$299364.0, down 458.05%, while the annual FY2025 figure was -$249728.0, 651.5% down from the prior year.
  • Change in Accured Expenses reached -$58348.0 in Q4 2025 per INM's latest filing, up from -$274066.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $765664.0 in Q4 2021 and bottomed at -$642392.0 in Q3 2024.
  • Average Change in Accured Expenses over 5 years is -$119721.6, with a median of -$131800.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: tumbled 253.19% in 2023, then surged 312.82% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $765664.0 in 2021, then tumbled by 145.66% to -$349611.0 in 2022, then surged by 169.04% to $241378.0 in 2023, then surged by 48.98% to $359614.0 in 2024, then crashed by 116.23% to -$58348.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$58348.0 in Q4 2025, -$274066.0 in Q3 2025, and -$5431.0 in Q2 2025.